glp 1 in australia GLP-1 RA and GIP + GLP-1 RA injections current evidence and uses – Dr. Victor Liew The rapid rise in the

GLP-1 medications support weight loss, but they arent enough for lasting weight loss on their own

From the approval of Orlistat (Xenical) in 1999, which focused on reducing dietary fat absorption, to the emergence of highly effective incretin-based therapies such as liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound), we have witnessed a fundamental shift in how obesity is understood and treated

Ensuring equitable access and strengthening health systems will be essential to prevent widening health disparities.AgendaCo-chairsDr Luz de Regil Director, Department of Nutrition and Food Safety, WHO and Dr Kirsten Bibbins Domingo Editor-in-Chief, JAMAModeratorDr Gaya Manori Gamhewage, Director, Department of Communication, WHOWelcomingDr Luz De Regil Director NFS, WHO and Dr Kirsten Bibbins-Domingo, Editor-in-Chief, JAMAPresentation:WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adultsDr Francesca Celletti, Senior Advisor Obesity, Department of Nutrition and Food Safety, WHO and Dr

Evidence-based guidance for clinicians.

GLP-1